Unicycive(US:UNCY) Globenewswire·2025-10-13 20:00Core Viewpoint - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. about a class action lawsuit due to alleged misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from March 29, 2024, to June 27, 2025 [3]. - Allegations include that Unicycive overstated its readiness to meet FDA manufacturing compliance and the regulatory prospects of its oxylanthanum carbonate new drug application [3]. - The deadline for shareholders to register for the class action is October 14, 2025 [4]. Group 2: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software for status updates throughout the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].